Influence of Candida colonization on the (1→3) β-D-glucan assay [4]

Clinical Infectious Diseases

Volumn 43, Issue 2, 2006, Pages 263-264

  Pontón, José ^a   Del Palacio, Amalia ^b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; GALACTOMANNAN; MANNAN;

ASSAY; CANDIDA; CANDIDIASIS; CLINICAL ARTICLE; FUNGAL COLONIZATION; FUNGAL DETECTION; FUNGUS CULTURE; HIGH RISK PATIENT; HUMAN; LABORATORY DIAGNOSIS; LETTER; MYCOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

BETA-GLUCANS; BIOLOGICAL ASSAY; CANDIDIASIS; HUMANS; MYCOSES;

EID: 33745714441     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/505306     Document Type: Letter

References (6)

1. Upton A, Leisenring W, Marr KA. (1→3) β-D-glucan assay in the diagnosis of invasive fungal infections [letter]. Clin Infect Dis 2006;42:1054-6.
2. Ostrosky-Zeichner L, Finkelman MA. Reply to Upton et al. [letter]. Clin Infect Dis 2006;42:1056.
3. Pazos C, Pontón J, del Palacio A. Contribution of (1→3)-β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43:299-305.
4. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immnosorbent assay for galactomannan, and (1→3)-β-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42:2733-41.
5. Klont RR, Meis JFG, Verweij PE. Critical assessment of issues in the diagnosis of invasive aspergillosis. Clin Microbiol Infect 2001; 7(Suppl 2):32-7.
6. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000; 110:273-84.